CIBC Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

CIBC Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-129,064	Closed	-$13.3M	–	1080
2022 Q3	$13.3M	Buy	+129,064	New	+$12.2M	0.06%	183
2021 Q4	–	Sell	-183,374	Closed	-$29.2M	–	1541
2021 Q3	$29.2M	Buy	183,374 +19,095	+12%	+$2.61M	0.12%	123
2021 Q2	$21.6M	Buy	+164,279	New	+$21.9M	0.09%	138

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

CIBC Asset Management's ASND Position: Q4 2022 in Review

CIBC Asset Management sold out of Ascendis Pharma A/S (ASND) in Q4 2022, closing a stake of 129,064 shares — an estimated $13.3M sold.

CIBC Asset Management first reported a position in ASND in Q2 2021 and held it in 3 quarters. The position peaked at $29.2M in Q3 2021. 187 funds tracked by Wall St. Rank hold ASND as of Q4 2022.

CIBC Asset Management reported no remaining Ascendis Pharma A/S position as of Q4 2022 after selling out during the quarter.
CIBC Asset Management sold 129,064 Ascendis Pharma A/S shares in Q4 2022, an estimated $13.3M.
CIBC Asset Management first reported a position in Ascendis Pharma A/S in Q2 2021 and held it in 3 quarters.
CIBC Asset Management's Ascendis Pharma A/S position peaked at $29.2M in Q3 2021.
187 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2022.

Based on CIBC Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.